Two Sigma Investments’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-521,965
Closed -$21M 5049
2026
Q1
$21M Sell
521,965
-40,396
-7% -$871K 0.02% 916
2025
Q4
$14.1M Buy
562,361
+310,293
+123% +$7.28M 0.02% 910
2025
Q3
$5.7M Sell
252,068
-154,845
-38% -$3.61M 0.01% 1344
2025
Q2
$7.04M Buy
406,913
+144,009
+55% +$2.67M 0.01% 1029
2025
Q1
$5.75M Buy
+262,904
New +$7.26M 0.01% 1047
2024
Q4
Sell
-58,783
Closed -$1.7M 3191
2024
Q3
$1.7M Buy
58,783
+31,237
+113% +$1.16M ﹤0.01% 1775
2024
Q2
$1.06M Buy
+27,546
New +$1.25M ﹤0.01% 1954
2022
Q4
Sell
-113,472
Closed -$7.75M 2786
2022
Q3
$7.75M Buy
+113,472
New +$6.71M 0.03% 585
2021
Q4
Sell
-362,204
Closed -$11.9M 4243
2021
Q3
$11.9M Sell
362,204
-112,834
-24% -$6.34M 0.03% 687
2021
Q2
$30M Buy
475,038
+90,307
+23% +$4.66M 0.07% 347
2021
Q1
$16.5M Buy
384,731
+179,991
+88% +$8.52M 0.04% 504
2020
Q4
$11.7M Sell
204,740
-106,240
-34% -$4.49M 0.03% 546
2020
Q3
$9.38M Sell
310,980
-238,558
-43% -$7.13M 0.03% 527
2020
Q2
$17.9M Buy
549,538
+118,199
+27% +$3.8M 0.09% 241
2020
Q1
$11.6M Buy
431,339
+214,562
+99% +$7.62M 0.09% 223
2019
Q4
$6.64M Buy
216,777
+71,464
+49% +$1.98M 0.02% 799
2019
Q3
$3.5M Buy
+145,313
New +$4M 0.01% 1062

Other funds holding APLS

Two Sigma Investments's APLS Position: Q2 2026 in Review

Two Sigma Investments sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 521,965 shares — an estimated $21M sold.

Two Sigma Investments first reported a position in APLS in Q3 2019 and held it in 17 quarters. The position peaked at $30M in Q2 2021. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Two Sigma Investments reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Investments sold 521,965 Apellis Pharmaceuticals shares in Q2 2026, an estimated $21M.
  • Two Sigma Investments first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 17 quarters.
  • Two Sigma Investments's Apellis Pharmaceuticals position peaked at $30M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.